azd0901
mAbexperimentalADC
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jan 16, 2023 (NCT05702229)
Timeline
Indications
Mechanism of action
- Claudin-18Immunity, passive
CLDN18 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068297 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07143604 | Phase 2 | Aug 29, 2025 | AstraZeneca |
| NCT07069712 | Phase 2 | Jul 17, 2025 | AstraZeneca, Parexel |
| NCT06346392 | Phase 3 | Mar 4, 2024 | AstraZeneca |
| NCT06219941 | Phase 2 | Dec 13, 2023 | AstraZeneca |
| NCT05702229 | Phase 2 | Jan 16, 2023 | AstraZeneca |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 5 | 5 | 2 | 2023 |
| Parexel | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1